Erratum: Preoperative evaluation of patients with liver disease (Nature Clinical Practice Gastroenterology & Hepatology (2007) vol. 4 (266-276) 10.1038/ncpgasthep0794);Preoperative evaluation of patients with liver disease

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 4, Issue 5, 2007, Pages 266-276

  Hanje, A James ^a   Patel, Tushar ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; DIURETIC AGENT; FENTANYL; HALOTHANE; ISOFLURANE; LACTULOSE; METRONIDAZOLE; MORPHINE; NARCOTIC ANALGESIC AGENT; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAXIMIN; VANCOMYCIN; VITAMIN K GROUP; ZINC;

ABDOMINAL SURGERY; ACUTE HEPATITIS; ANESTHESIA; ASCITES; BLOOD CLOTTING DISORDER; BRAIN DISEASE; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; EMERGENCY SURGERY; HEART SURGERY; HUMAN; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER RESECTION; LIVER SURGERY; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; OBSTRUCTIVE JAUNDICE; PATIENT SELECTION; PORTAL HYPERTENSION; PREDICTION; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SCREENING; SURGICAL RISK; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

EID: 34248197097     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0873     Document Type: Erratum

References (87)

1. Garrison RN et al. (1984) Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. Ann Surg 199: 648-655
2. Schemel WH (1976) Unexpected hepatic dysfunction found by multiple laboratory screening. Anesth Analg 55: 810-812
3. Hay JE et al. (1989) The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 9: 193-197
4. Hultcrantz R et al. (1986) Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 21: 109-113
5. Delco F (2005) Dose adjustment in patients with liver disease. Drug Saf 28: 529-545
6. McIntyre N et al. (1996) Cirrhosis, portal hypertension and ascites. In Oxford Textbook of Medicine, edn 3 (eds Weatherall DJ et al. New York: Oxford University Press
7. Tegeder I et al. (1999) Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 37: 17-40
8. Pentikainen PJ et al. (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29: 272-277
9. Ghabrial H et al. (1986) The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 30: 93-97
10. Ochs HR et al. (1983) Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation. Clin Pharmacol Ther 33: 471-476
11. Gelman S (1984) Liver circulation and function during isoflurane and halothane anesthesia. Anesthesiology 61: 726-730
12. Kenna JG (1997) Immunoallergic drug-induced hepatitis: Lessons from halothane. J Hepatol 26: 5-12
13. Groszmann RJ (1994) Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. Hepatology 20 1359-1363
14. Moller S and Henriksen JH (2002) Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 87: 9-15
15. Gelman SI (1976) Disturbances in hepatic blood flow during anesthesia and surgery. Arch Surg 111: 881-883
16. Patel T (1999) Surgery in the patient with liver disease. Mayo Clin Proc 74: 593-599
17. Friedman LS and Maddrey WC (1987) Surgery in the patient with liver disease. Med Clin North Am 71: 453-476
18. Dixon JM et al. (1983) Factors affecting morbidity and mortality after surgery for obstructive jaundice: A review of 373 patients. Gut 24: 845-852
19. Blamey SL et al. (1983) Prediction of risk in biliary surgery. Br J Surg 70: 535-538
20. Lai EC et al. (1992) Surgery for malignant obstructive jaundice: analysis of mortality. Surgery 112: 891-896
21. Harville DD and Summerskill WH (1963) Surgery in acute hepatitis. Causes and effects. JAMA 184: 257-261
22. Powell-Jackson P et al. (1982) Adverse effects of exploratory laparotomy in patients with unsuspected liver disease. Br J Surg 69: 449-451
23. Greenwood SM et al. (1972) The increased mortality rate of open liver biopsy in alcoholic hepatitis. Surg Gynecol Obstet 134 600-604
24. Runyon BA (1986) Surgical procedures are well tolerated by patients with asymptomatic chronic hepatitis. J Clin Gastroenterol 8: 542-544
25. Hargrove MD Jr (1970) Chronic active hepatitis: Possible adverse effect of exploratory laparotomy. Surgery 68: 771-773
26. Higashi H et al. (1994) Influence of viral hepatitis status on operative morbidity and mortality in patients with primary hepatocellular carcinoma. Br J Surg 81: 1342-1345
27. Behms KE et al. (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2: 292-298
28. Child CG and Turcotte JG (1964) Surgery and portal hypertension. Major Probl Clin Surg 1: 1-85
29. Pugh RN et al. (1973) Transaction of the oesophagus for bleeding oesophageal varices. Br J Surg 60: 646-649
30. Ziser A et al. (1999) Morbidity and mortality in cirrhotic patients undergoing anesthesia and surgery. Anesthesiology 90 42-53
31. del Olmo JA et al. (2003) Risk factors for nonhepatic surgery in patients with cirrhosis. World J Surg 27: 647-652
32. Mansour A et al. (1977) Abdominal operations in patients with cirrhosis: Still a major surgical challenge. Surgery 122: 730-735
33. Gines P et al. (1987) Compensated cirrhosis: Natural history and prognostic factors. Hepatology 7: 122-128
34. Malinchoc M et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871
35. Wiesner RH et al. (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124: 91-96
36. Kamath PS et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33: 464-470
37. Chalasani N et al. (2002) Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceall bleeding. Hepatology 35: 1282-1284
38. Sheth M et al. (2002) Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2: 2
39. Perkins L et al. (2004) Utility of preoperative scores for predicting morbidity after cholecystectomy in patients with cirrhosis. Clin Gastroenterol Hepatol 2: 1123-1128
40. Suman A et al. (2004) Predicting outcome after cardiac surgery in patients with cirrhosis: A comparison of Child-Pugh and MELD scores. Clin Gastroenterol Hepatol 2: 719-723
41. Farnsworth N et al. (2004) Child-Turcotte-Pugh versus MELD score as a predictor of outcome after elective and emergent surgery in cirrhotic patients. Am J Surg 188: 580-583
42. Befeler AS et al. (2005) The safety of intra-abdominal surgery in patients with cirrhosis: Model for End-Stage Liver Disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg 140: 650-654
43. Northup PG et al. (2005) Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 242: 244-251
44. Kim YK et al. (1997) Prediction of postoperative decompensated liver function by technetium-99m galactosyl-human serum albumin liver scintigraphy in patients with hepatocellular carcinoma complicating chronic liver disease. Br J Surg 84: 793-796
45. Ravaioli M et al. (2003) Operative risk by the lidocaine test (MEGX} in resected patients for HCC on cirrhosis. Hepatogastroenterology 50: 1552-1555
46. Gill RA et al. (1983) Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 198: 701-704
47. Wahlstrom K et al. (2000) Trauma in cirrhotics: Survival and hospital sequelae in patients requiring abdominal exploration. Am Surg 66: 1071-1076
48. Christmas AB et al. (2005) Cirrhosis and trauma: A deadly duo. Am Surg 71: 996-l000
49. McSherry CK et al. (1980) The incidence and causes of death following surgery for nonmalignant biliary tract disease. Ann Surg 191: 271-275
50. Metcalf AT et al. (1987) The surgical risk of colectomy in patients with cirrhosis. Dis Colon Rectum 30: 529-531
51. Bloch RS et al. (1985) Cholecystectomy in patients with cirrhosis. A surgical challenge. Arch Surg 120: 669-672
52. Sleeman D et al. (1998) Laparoscopic cholecystectomy in cirrhotic patients. J Am Coll Surg 187: 400-403
53. Azoulay D et al. (2001) Neoadjuvant transjugular intrahepatic portosystemic shunt: A solution for extrahepatic abdominal operation in cirrhotic patients with severe portal hypertension. J Am Coll Surg 193: 46-51
54. Gil A et al. (2004) The role of transjugular intrahepatic portosystemic shunt prior to abdominal tumoral surgery in cirrhotic patients with portal hypertension. Eur J Surg Oncol 30: 46-52
55. Klemperer JD et al. (1998) Cardiac operations in patients with cirrhosis. Ann Thorac Surg 65: 85-87
56. Hayashida N et al. (2004) Clinical outcome after cardiac operations in patients with cirrhosis. Ann Thorac Surg 77: 500-505
57. Capussotti L et al. (1998) Operative risks of major hepatic resections. Hepatogastroenterology 45: 184-190
58. Grazi GL et al. (2001) Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234: 71-78
59. Bruix J et al. (1996) Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. Gastroenterology 111: 1018-1022
60. Bruix J and Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236
61. Schroeder RA et al. (2006) Predictive indices of morbidity and mortality after liver resection. Ann Surg 243: 373-379
62. French CJ et al. (2003) Cryoprecipitate for the correction of coagulopathy associated with liver disease. Anaesth Intensive Care 31: 357-361
63. Bernstein DE et al. (1997) Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 113: 1930-1937
64. Jeffers L et al. (2002) Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 123: 118-126
65. Levy JH et al. (2006) Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: Review of safety profile. Transfusion 46: 919-933
66. Shao YF et al. (2006) Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: A multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 191: 245-249
67. Burroughs AK et al. (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 291: 1377-1381
68. Riou JP et al. (1992) Factors influencing wound dehiscence. Am J Surg 163: 324-330
69. Runyon BA (2004) Management of adult patients with ascites due to cirrhosis. Hepatology 39: 841-856
70. Moreau R et al. (2007) Diagnosis and treatment of acute renal failure in patients with cirrhosis. Best Pract Res Clin Gastroenterol 21: 111-123
71. Blei AT et al. (2001) Hepatic encephalopathy. Am J Gastroenterol 96: 1968-1976
72. Als-Nielsen B et al. (2004) Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials. BMJ 328: 1046
73. Mas A et al. (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38: 51-58
74. Reding P et al. (1984) Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 2: 493-495
75. Bresci G et al. (1993) Management of hepatic encephalopathy with oral zinc supplementation: A long-term treatment. Eur J Med 2 414-416
76. DiCecco SR et al. (1989) Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc 64: 95-102
77. Schenk P et al. (2003) Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 125: 1042-1052
78. Mazzeo AT et al. (2004) Hepatopulmonary syndrome: A concern for the anesthetist? Pre-operative evaluation of hypoxemic patients with liver disease. Acta Anaesthesiol Scand 48: 178-186
79. Deibert P et al. (2006) Hepatopulmonary syndrome in patients with chronic liver disease: Role of pulse oximetry. BMC Gastroenterol 6: 15
80. Hoeper MM et al. (2004) Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 383: 1461-1468
81. Krowka MJ (2005) Hepatopulmonary syndrome and portopulmonary hypertension: Implications for liver transplantation. Clin Chest Med 26: 587-597
82. Krowka MJ et al (1999) Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30: 641-648
83. Hatfield AR et al. (1982) Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 2: 896-899
84. McPherson GA et al. (1984) Pre-operative percutaneous transhepatic biliary drainage: The results of a controlled trial. Br J Surg 71: 371-375
85. Pitt HA et al. (1985) Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 201: 545-553
86. Lai EC et al. (1994) Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 81: 1195-1198
87. Lai EC et al. (1992) Endoscopic biliary drainage for severe acute cholangitis. N Engl J Med 326: 1582-1586